

FAQs for Pharmacists




Toujeo[®]
Max SoloStar[®]
insulin glargine injection 300 Units/mL


900
UNIT
CAPACITY


56
DAY
SHELF LIFE^{†}**

PATIENTS
CAN START
AS LOW AS

20
UNITS
PER DAY[‡]



*Once opened, store at room temperature (below 86°F).

†Longer shelf life if unopened.

‡Recommended for patients requiring at least 20 units per day.

§The recommended starting dose of Toujeo in insulin-naïve patients with type 2 diabetes is 0.2 units per kilogram of body weight once daily.

Toujeo is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 6 years and older with diabetes mellitus.

Limitations of Use: Toujeo is not recommended for the treatment of diabetic ketoacidosis.

Important Safety Information

Contraindications

Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of the excipients in Toujeo.

Warnings and Precautions

Toujeo contains the same active ingredient, insulin glargine, as Lantus. The concentration of insulin glargine in Toujeo is 300 units per mL (U-300).

Insulin pens and needles must never be shared between patients. Do NOT reuse needles.

Please see full Important Safety Information for Toujeo inside.
Please see accompanying full [Prescribing Information](#).

1 What is the Toujeo® Max SoloStar® pen?

Toujeo Max SoloStar is a **pen option** recommended for appropriate adult patients with diabetes who require at least 20 Units of basal insulin per day. It provides the same Toujeo product, just in a modified device. The higher capacity Toujeo pen (**900 U**) means¹:

- Fewer pens to store
- Delivery of up to 160 Units in a single injection
- Fewer injections for patients who require more than 80 Units of basal insulin per dose

2 Does it replace the Toujeo® SoloStar® pen?

No, you can **continue providing Toujeo SoloStar to appropriate patients**. However, the Toujeo Max SoloStar pen might be a more appropriate option for patients who require at least 20 Units of basal insulin per day, based on the average daily dose and amount of insulin they are prescribed in a 30-day prescription.

3 How is Toujeo Max Solostar ordered?

The two Toujeo pens have **different NDC numbers** to choose from. Be sure to check your patient's prescription and **select the correct NDC number for each patient**:

 Toujeo® Max SoloStar® insulin glargine injection 300 Units/mL	 Toujeo® SoloStar® insulin glargine injection 300 Units/mL
NDC: 0024-5871-02	NDC: 0024-5869-03
300 Units/mL formulation	300 Units/mL formulation
3 mL and 900 Units per pen	1.5 mL and 450 Units per pen
2 pens (6 mL and 1800 Units total) per box	3 pens (4.5 mL and 1350 Units total) per box

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens only under medical supervision. Changes in insulin regimen, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia. Dosage adjustments are recommended to lower the risk of hypoglycemia when switching patients to Toujeo from another insulin therapy.

Please see full Important Safety Information for Toujeo on pages 6 and 7.

Please see accompanying full Prescribing Information.

4 Are there any differences in administering Toujeo with Toujeo Max SoloStar?


Yes. The most significant difference in administration with Toujeo Max SoloStar is that **one click delivers 2 Units of Toujeo** compared to 1 Unit with Toujeo SoloStar. Other differences are that Toujeo Max SoloStar delivers up to 160 Units in a single injection, and its dial extension is half the length of the current Toujeo SoloStar.¹

5 Is there any change in the Toujeo product?

Not at all—it's the exact same Toujeo formulation already offered to Toujeo SoloStar patients. This is another administration option for appropriate patients.

6 How do the two Toujeo pens compare?

Toujeo Max SoloStar holds **double the capacity** and offers **double the maximum dose** of Toujeo SoloStar in a single injection.¹



The pens also share key features:

- Same pen size
- 5-second hold time⁶
- 56-day shelf life¹
- Lowest injection volume of any basal insulin^{1-5*}
- Known SoloStar® platform

*On a unit-for-unit basis.

7 What should I do if I determine that Toujeo (insulin glargine) injection 300 Units/mL Max SoloStar is more cost-effective for a patient who's currently using Toujeo SoloStar?

Toujeo Max SoloStar is another pen option recommended for appropriate patients requiring at least 20 Units per day of Toujeo. If a patient prescribed Toujeo meets these criteria, contact the patient's doctor's office to inquire about switching the patient to Toujeo Max SoloStar. Toujeo Max SoloStar has per unit price parity with Toujeo SoloStar and comparable managed care coverage. Please also be sure to **remind the doctor that Toujeo Max SoloStar dials in 2-Unit increments**—so the patient's dose, if previously an odd number, will need to be adjusted up or down 1 Unit if changing to the new pen.¹

8 How do I dispense a 30-day supply of Toujeo Max SoloStar?

First, determine the maximum number of daily units a patient might take in a month's time, based on his/her prescription. Then use the conversion chart below to determine the number of boxes needed for the month. Please note: Each box is for single patient use only.

Each box of Toujeo Max SoloStar contains 2 pens and 1800 Units.

Units per Day	Boxes Required (NDC 0024-5871-02)	mL/Units per Box (2 Pens in Each Box)
Up to 60	1	6 mL/1800 Units
61-120	2	12 mL/3600 Units
121-180	3	18 mL/5400 Units

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.

Please see full Important Safety Information for Toujeo on pages 6 and 7. Please see accompanying full [Prescribing Information](#).

9 Are different needles required for the Toujeo Max SoloStar pen, and are the needles included in each pack?

Even though Toujeo Max SoloStar is another option, **it uses the same needles you currently use with Toujeo SoloStar**. And just as with Toujeo SoloStar, needles are not included with each pack.

When filling the needle prescription, make sure that patients receive the correct type and number of needles. Remember to instruct all patients to never withdraw Toujeo from the SoloStar disposable prefilled pen with a syringe and to **never reuse needles**:

- A new sterile needle must be used for each injection
- Reusing needles increases the risk of blocked needles, which may cause underdosing or overdosing
- Using a new sterile needle for each injection also minimizes the risk of contamination and infection

10 Is there a difference in average shelf life between the two pens?

No, the shelf life of both pens, once opened, is 56 days at room temperature, below 86°F (30°C).¹

11 Are there any different storage requirements for Toujeo Max SoloStar?

No changes there. You can store Toujeo Max SoloStar just as you do Toujeo SoloStar. Patients may find, however, that they have **fewer pens to store if prescribed Toujeo Max SoloStar**, because of its higher capacity. As always with Toujeo, please follow these guidelines:

UNOPENED PEN:

- Store in the refrigerator with pen cap on at a temperature between 36°F and 46°F (2°C and 8°C) in the box it came in
- Do not freeze
- Can be refrigerated until expiration date
- Discard after expiration date has passed

OPENED PEN:

- Keep at room temperature below 86°F (30°C)
- Do not refrigerate an opened Toujeo SoloStar pen
- Discard 56 days after first use, even if pen still contains insulin
- Keep out of direct heat and light

Toujeo is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 6 years and older with diabetes mellitus.

Limitations of Use: Toujeo is not recommended for the treatment of diabetic ketoacidosis.

Important Safety Information for Toujeo U-300 (insulin glargine) injection

Contraindications

Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of the excipients in Toujeo.

Warnings and Precautions

Toujeo contains the same active ingredient, insulin glargine, as Lantus. The concentration of insulin glargine in Toujeo is 300 units per mL (U-300).

Insulin pens and needles must never be shared between patients. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens only under medical supervision. Changes in insulin regimen, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia. Dosage adjustments are recommended to lower the risk of hypoglycemia when switching patients to Toujeo from another insulin therapy.

Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.

Unit for unit, patients started on, or switched to, Toujeo required a higher dose than patients controlled with Lantus. When switching from another basal insulin to Toujeo, patients experienced higher average fasting plasma glucose levels in the first few weeks of therapy until titrated to their individualized fasting plasma glucose targets. Higher doses were required in titrate-to-target studies to achieve glucose control similar to Lantus.

Hypoglycemia is the most common adverse reaction in patients treated with Toujeo and may be life-threatening. The long-acting effect of Toujeo may delay recovery from hypoglycemia compared to shorter-acting insulins.

Medication errors that may lead to hypoglycemia, such as accidental mix-ups between insulin products, have been reported. Patients should be instructed to always verify the insulin label before each injection.

Do not dilute or mix Toujeo with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Toujeo via an insulin pump or intravenously because severe hypoglycemia can occur.

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Toujeo, monitor, and treat if indicated.

A reduction in the Toujeo dose may be required in patients with renal or hepatic impairment.

All insulins, including Toujeo, can lead to life-threatening hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dosage adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Adverse reactions commonly associated with Toujeo include hypoglycemia, hypersensitivity reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain.


Important Safety Information for Toujeo U-300 (insulin glargine) injection SoloStar and Toujeo Max SoloStar

Toujeo SoloStar and Toujeo Max SoloStar are single-patient-use prefilled insulin pens. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying their pen; otherwise, they may not get the correct amount of insulin, which may affect their blood glucose levels. It is especially important to perform a safety test when a patient is using a new pen for the first time.

Do not withdraw Toujeo from the SoloStar and Max SoloStar single-patient-use prefilled pens with a syringe.

Please see accompanying full [Prescribing Information](#).

References: 1. Toujeo Prescribing Information. 2. Basaglar Prescribing Information. 3. Lantus Prescribing Information. 4. Levemir Prescribing Information. 5. Tresiba Prescribing Information. 6. Toujeo Max SoloStar Instructions for Use.




Toujeo[®]
insulin glargine injection 300 Units/mL

The highest capacity basal insulin pen on the market¹⁻⁵


Toujeo® Max SoloStar®
insulin glargine injection 300 Units/mL



Cartridge:
900 U¹

Max dose:
160 U per
injection¹

Adjust
by 2 U¹

Half-length
dial extension

It also shares features with Toujeo SoloStar:

- Same pen size
- 5-second hold time⁶
- 56-day shelf life¹
- Lowest injection volume of any basal insulin^{1-5*}
- Known SoloStar platform

*On a unit-for-unit basis.

Calculate Starting Dose at

<https://www.toujeopro.com/toujeo-insulin-dosing-and-titration-calculator>



Important Safety Information

Contraindications

Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of the excipients in Toujeo.

Please see full Important Safety Information for Toujeo on pages 6 and 7.

Please see accompanying full [Prescribing Information](#).